Compare LBRDA & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LBRDA | RYTM |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | United States |
| Employees | 1900 | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 5.8B |
| IPO Year | N/A | 2017 |
| Metric | LBRDA | RYTM |
|---|---|---|
| Price | $34.99 | $108.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $131.14 |
| AVG Volume (30 Days) | 189.0K | ★ 862.0K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $55.34 |
| Revenue Next Year | $109.28 | $86.06 |
| P/E Ratio | $8.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.18 | $62.84 |
| 52 Week High | $100.71 | $122.20 |
| Indicator | LBRDA | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 56.76 | 75.51 |
| Support Level | $31.91 | $98.30 |
| Resistance Level | $34.90 | $113.03 |
| Average True Range (ATR) | 1.59 | 5.27 |
| MACD | 0.54 | 2.16 |
| Stochastic Oscillator | 55.73 | 90.73 |
Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services, including video, internet, voice, and mobile services; commercial services, including small and medium business and enterprise solutions; advertising services; and other services. The company's reportable segments are GCI Holdings and Charter. The firm derives the majority of its revenue from GCI Holdings.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.